Hot Mandates: Israel-Based Venture Capital

8 Feb

An Israel-based venture capital firm whose sole LP is the CK Hutchison Holdings group. The group operates the world’s largest international health and beauty retailer. With over 15,700 stores in 25 markets in Europe and Asia. The firm looks to provide a unique stepping stone for successful companies to broaden their global reach. The firm offers partners deep understanding of relevant audiences and a unique opportunity for truly innovative, trail-blazing consumer-related digital health ventures. The firm is looking to invest in digital therapeutics, POC diagnostics, and other dHealth companies from seed stage and beyond. The firm is interested in companies with well defined, relevant products and solutions, preferably with initial validation or proof-of-concept. The firm invests globally, and is flexible to the size of investment, depending on the needs of the company.

Within the digital health and POC diagnostics space, the firm has many areas of interest. These include, but are not limited to, telemedicine, remote monitoring, patient adherence, FemTech and aging. The firm will also invest in digital therapeutics, with no drug-based component, which may require prescription.

The firm has no specific requirements for company and management team, and makes decisions on a case-by-case basis. The firm can lead or co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

Hot Mandates: UK-Based non-profit organization

8 Feb

Based in London, the group is the largest membership-based non-profit organization in the world dedicated to finding a cure and improving life for everyone affected by Parkinson’s disease. The group originally focused on research grants, but is now implementing a venture philanthropy model with an evergreen structure that provides funding to biotech startups from an annual budget called the Virtual Biotech program. For 2019-2024, this program looks to invest about $30M into for-profit early stage biotech companies working on Parkinson’s therapies. The group does look for some type of return, but is extremely flexible with the size and structure of investments, ranging up to about $2M per company/project and may employ convertible notes, rights/options, capped royalties, etc. The group is primarily focused on companies located in North America or Europe and will co-invest with VCs and professional investors.

The group is exclusively focused on therapeutics companies working on drugs for treating/curing Parkinson’s disease. The group will fund projects that are targeting related neurodegenerative diseases that have potential in Parkinson’s or are pursuing Parkinson’s in parallel. Also, the group will invest in assets that are being repurposed for Parkinson’s. The group will invest from discovery up unto Ph. IIa clinical trials.

The group has no strict company or management requirements and will invest in early-stage project as well as established companies. The group may or may not seek a board seat along with investment depending on the stage and needs of the company as well as the level of involvement they look to play in the company’s development.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

Hot Mandates: Europe & US based Venture Capital seeks

8 Feb

A venture capital firm headquartered in Paris with offices and partners in San Francisco, New York and London. The firm is investing out of its first, 2015-vintage, $275M fund and makes both seed/venture and growth stage investments ranging from $500k – $20M. The firm typically prefers straight equity investments, but will also consider convertible note financings. The firm has a fairly broad mandate, and invests evenly among enterprise software, fintech, consumer and digital health sectors. The fund’s LPs are large insurance companies, and along with capital, the firm looks to add value by providing portfolio companies direct introductions to these groups to help scale and realize their potential.

The firm plans to have digital health companies make up roughly 25% of its portfolio and will invest in consumer and B2B healthcare IT and tech-enabled health services. It is a requirement that the technology has utility for payers and providers. Some of the firm’s digital health portfolio companies include a behavior change platform that partners with insurers, Accountable Care Organizations (ACO) and Self-insured employers to provide research-based behavioral incentives for members to better manage their chronic conditions.

The firm invests in global early-stage companies with annual revenues under $5M as well as growth stage companies with annual revenues exceeding $5M. The firm will consider pre-revenue companies with strong management teams and previously successful entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

Hot Mandate: US Based Private Investment With Accelerator Arm Interested In Medtech & Digital Health, Including AI & Big Data

5 Feb

A private/family investment vehicle based in US makes seed investments via an accelerator arm, and also has a stage-agnostic fund. Seed investments are typically $25,000-100,000, and the firm is capable of making larger investments via the fund. The firm also provides an accelerator program, and works with partners in the healthcare industry to strategically invest in startups. The firm will consider investing in companies worldwide.

The firm is interested in investing in digital health and medical technology, and invests in subsectors in which the firm and its industry partners can apply expertise; within medical devices, typically this means products that have a significant software component, including biosensors, wearables and health monitoring devices. Within digital health, the firm’s interests include the following areas: Care Management, Hospital Workflow, Diagnostics, A.I. & Big Data, Population Health, Patient Adherence,Telemedicine. The firm is interested in both consumer applications and enterprise software. The firm works with strategic partners (including major pharma companies and health systems) to identify focus areas for innovation.

The firm prefers to invest in companies with at least two co-founders, one with technical expertise and one with business expertise; for the accelerator program in particular, the firm prefers to work with companies that have a technical expert co-founder. In addition to due diligence on the management team and technology, the firm also considers a product’s potential market opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Hot Mandate: Canada Based VC Invests In Therapeutics, Medical Devices & AI/Digital Health, With Special Interest in Precision Medicine & AI in Therapeutics Development

5 Feb

A venture capital firm with multiple offices in Canada recently launched a $200M (CAD) fund, through which the firm will invest around 80% in Canada-based life science companies and 20% in USA/global companies. The firm will generally participate in Series A financing rounds and beyond, including crossover and IPO; average check sizes will be around $5-10M CAD, with a total of $15-20M CAD will be reserved for follow-on investments. In addition, the firm is also dedicated to company incubation and creation for which the firm will work with earlier stage companies and deploy smaller amounts of capital (around $1M CAD).

The firm has a general theme of investing in precision medicine – technologies that can enhance the quality and accuracy of diagnoses, enable more precise and personalized treatments, targeted therapies such as cell & gene therapy, technologies that leverage AI to accelerate therapeutic development, etc. In terms of sector, the firm seeks to invest 50-60% in therapeutics, 20-30% in medical devices, and 10-15% in AI/digital health/diagnostics. For medical devices, the firm prefers later stage opportunities that are close to commercialization. The firm does not focus on any particular indication area.

The firm does not have specific company or management team requirements. While the firm likes to see management teams with a successful track record and wide range of experiences, this is not required and the firm is open to working on inexperienced management teams. The firm is capable of leading or co-leading investment rounds, and is also open to co-investing with likeminded investors. The firm is very hands-on and leverages their network to actively support the growth of their portfolio companies and provide needed resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Hot Mandate: Hong Kong Based boutique VC Invests in All Sectors of Healthcare Technologies, Most Interested In Areas Including AI In Medtech

5 Feb

A boutique venture capital firm founded in 2015 in Hong Kong currently manages a 150M USD fund and a 200M RMB fund. The fund is industry agnostic within China while it focuses only on healthcare ex-China. The firm generally participates in Series A or B rounds but would also consider seed and growth-stage funding. Typical equity investment size ranges from $1-5M. The firm is open to both leading and co-investing, and is actively seeking new opportunities from across the world with a focus on companies in China, U.S., Europe, and Israel. The firm helps portfolio companies get into massive and fast-growing markets of China and Asia, and assists Chinese companies to expand abroad.

The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics,

the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.

The firm is in search of ambitious companies with strong, experienced management teams and takes a hands-on approach to portfolio companies and can work with incomplete teams and can contribute expertise in essential services: branding, marketing, channel development, overseas expansion, human resources and finance. The firm may also request distribution or negotiation rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Fill Your Fundraising Dance Card with These Investors

4 Feb

By Rory McCann, Marketing Manager & Conference Producer, LSN

For more than eight years, Life Science Nation (LSN) has hosted the go-to partnering events that have provided attendees with what they seek most, but rarely get with networking conferences: a well-matched meeting. LSN’s premier partnering system has helped raise millions of dollars for early-stage companies in life science and healthcare by matching fundraising founders with investors and strategic partners based on product fit and stage of development.

Healthtech Partnering Week (HPW), March 15-19 is right around the corner, and we are thrilled to host enthusiastic, active investors and service providers passionate about advancing products and services that help patients live well. Check out our growing list of confirmed investors joining us and sign up by February 19 to save on our early bird rates.

Confirmed HPW Investors

Confirmed RESI Investors Confirmed 4D Meets AI Investors Confirmed LHI Investors

 

 

← Older Entries
Newer Entries →